Recently, researchers have argued that the PI3K-AKT pathway requires RTK-induced activation, usually involving SHP2 as a critical mediator in KRAS-mutant cancers (Ebi et al., 2011; Navas et al., 2012; Hao et al., 2019). The gene discussed is PIK3CA; the disease is cancer.